BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018

Thu, Apr 12, 2018 08:00 CET

Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 on Thursday, April 26, 2018 at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on April 26, at 09:30 – 10:30 a.m. CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – March 2018 followed by a Q&A-session. To attend, please dial-in at one of the numbers below from:Sweden: + 46 8

There are no items matching the current filter

There are no more items matching the current filter

Back to top

About Us

Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018

Subscribe

Media

Share

About Us

Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018

Subscribe

Media